3 Asian Stocks Estimated To Be Trading At Up To 47.5% Below Intrinsic Value
Amidst geopolitical tensions and fluctuating oil prices, Asian markets have shown resilience, with some indices experiencing gains despite broader global uncertainties. In this environment, identifying undervalued stocks can be a strategic approach for investors seeking potential opportunities, as these stocks may offer value relative to their intrinsic worth amidst current market conditions.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Shoucheng Holdings (SEHK:697) | HK$1.68 | HK$3.25 | 48.3% |
| Rakuten Bank (TSE:5838) | ¥5648.00 | ¥11166.73 | 49.4% |
| Rakus (TSE:3923) | ¥1030.00 | ¥2036.90 | 49.4% |
| OVERLAP HoldingsInc (TSE:414A) | ¥850.00 | ¥1673.74 | 49.2% |
| Nippon Thompson (TSE:6480) | ¥1776.00 | ¥3476.01 | 48.9% |
| Moshi Moshi Retail Corporation (SET:MOSHI) | THB39.75 | THB77.17 | 48.5% |
| Loncin Motor (SHSE:603766) | CN¥13.95 | CN¥27.33 | 48.9% |
| Hana Technology (KOSDAQ:A299030) | ₩12170.00 | ₩23694.42 | 48.6% |
| Guming Holdings (SEHK:1364) | HK$21.88 | HK$42.78 | 48.9% |
| CanSino Biologics (SEHK:6185) | HK$23.40 | HK$45.52 | 48.6% |
Underneath we present a selection of stocks filtered out by our screen.
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)
Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas both in China and internationally, with a market cap of approximately HK$122.74 billion.
Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to approximately CN¥2.06 billion.
Estimated Discount To Fair Value: 47.5%
Sichuan Kelun-Biotech Biopharmaceutical is trading at HK$513.5, significantly below its estimated future cash flow value of HK$977.28, suggesting it may be undervalued based on cash flows. The company is forecast to grow revenue rapidly at 31.3% annually, outpacing the Hong Kong market average of 8.7%. Recent developments include receiving approval for clinical trials of innovative drugs like SKB565 and HBM7575/SKB575, enhancing its pipeline in oncology and respiratory treatments.
- Our comprehensive growth report raises the possibility that Sichuan Kelun-Biotech Biopharmaceutical is poised for substantial financial growth.
- Click here and access our complete balance sheet health report to understand the dynamics of Sichuan Kelun-Biotech Biopharmaceutical.
Akeso (SEHK:9926)
Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of antibody drugs globally with a market cap of HK$90.82 billion.
Operations: The company's revenue is primarily derived from the research, development, production, and sale of biopharmaceutical products, totaling CN¥3.06 billion.
Estimated Discount To Fair Value: 45.5%
Akeso is trading at HK$98.6, significantly below its estimated future cash flow value of HK$180.92, highlighting potential undervaluation based on cash flows. The company's revenue is projected to grow at 28.6% annually, surpassing the Hong Kong market average of 8.7%. Recent collaborations and product developments, such as the cadonilimab-based study with Memorial Sloan Kettering Cancer Center and ivonescimab's promising clinical results in NSCLC treatment, bolster its innovative oncology pipeline.
- The analysis detailed in our Akeso growth report hints at robust future financial performance.
- Take a closer look at Akeso's balance sheet health here in our report.
GKG Precision Machine (SZSE:301338)
Overview: GKG Precision Machine Co., Ltd. specializes in providing precision automation equipment both in China and internationally, with a market cap of CN¥14.09 billion.
Operations: GKG Precision Machine Co., Ltd. generates revenue through its precision automation equipment offerings, serving both domestic and international markets.
Estimated Discount To Fair Value: 44.4%
GKG Precision Machine is trading at CN¥94.56, well below its estimated future cash flow value of CN¥170.12, suggesting undervaluation based on cash flows. The company's earnings are forecast to grow significantly at 34.4% annually, outpacing the Chinese market's 25.9%. Despite recent share price volatility, GKG's strong revenue and profit growth prospects make it a compelling consideration for investors focused on undervalued stocks with robust cash flow potential in Asia. Recent bylaw changes may impact internal investment strategies.
- Our growth report here indicates GKG Precision Machine may be poised for an improving outlook.
- Click here to discover the nuances of GKG Precision Machine with our detailed financial health report.
Make It Happen
- Access the full spectrum of 220 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com